Cutaneous reactions after COVID ‐19 vaccination in Turkey: A multicenter study
Yazarlar (21)
Filiz Cebeci Kahraman
Türkiye
Türkiye
Sevil Savaş Erdoğan
Türkiye
Türkiye
Nurhan Döner Aktaş
Dr. Öğr. Üyesi Hülya Albayrak Türkiye
Dursun Türkmen Türkiye
Murat Borlu Türkiye
Deniz Aksu Arıca Türkiye
Abdullah Demirbaş Türkiye
Prof. Dr. Atiye AKBAYRAK Tokat Gaziosmanpaşa Üniversitesi, Türkiye
Algün Polat Ekinci Türkiye
Gözde Emel Gökçek
Türkiye
Türkiye
Havva Hilal Ayvaz Çelik
Türkiye
Türkiye
Mustafa Kaan Taşolar
Türkiye
Türkiye
İsa An Türkiye
Selami Aykut Temiz Türkiye
Emel Hazinedar
Erhan Ayhan Türkiye
Dr. Öğr. Üyesi Pelin Hızlı Türkiye
Doç. Dr. Eda Öksüm Solak Türkiye
Fatma Arzu Kılıç Türkiye
Ertan Yılmaz Türkiye
| Makale Türü |
Özgün Makale
(SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale)
|
||
| Dergi Adı | Journal of Cosmetic Dermatology (Q4) | ||
| Dergi ISSN | 1473-2130 Wos Dergi Scopus Dergi | ||
| Dergi Tarandığı Indeksler | SCI-Expanded | ||
| Makale Dili | İngilizce | Basım Tarihi | 07-2022 |
| Cilt / Sayı / Sayfa | 21 / 9 / 3692–3703 | DOI | 10.1111/jocd.15209 |
| Makale Linki | http://dx.doi.org/10.1111/jocd.15209 | ||
| UAK Araştırma Alanları |
Deri ve Zührevi Hastalıkları
|
||
| Özet |
| AbstractObjectivesIn this study covering all of Turkey, we aimed to define cutaneous and systemic adverse reactions in our patient population after COVID‐19 vaccination with the Sinovac/CoronaVac (inactivated SARS‐CoV‐2) and Pfizer/BioNTech (BNT162b2) vaccines.MethodsThis prospective, cross‐sectional study included individuals presenting to the dermatology or emergency outpatient clinics of a total of 19 centers after having been vaccinated with the COVID‐19 vaccines. Systemic, local injection site, and non‐local cutaneous reactions after vaccination were identified, and their rates were determined.ResultsOf the 2290 individuals vaccinated between April 15 and July 15, 2021, 2097 (91.6%) received the CoronaVac vaccine and 183 (8%) BioNTech. Systemic reactions were observed at a rate of 31.0% after the first CoronaVac dose, 31.1% after the second CoronaVac dose, 46.4% after the first BioNTech dose, and 46.2% after the second BioNTech dose. Local injection site reactions were detected at a rate of 35.6% after the first CoronaVac dose, 35.7% after the second CoronaVac dose, 86.9% after the first BioNTech dose, and 94.1% after the second BioNTech dose. A total of 133 non‐local cutaneous reactions were identified after the CoronaVac vaccine (2.9% after the first dose and 3.5% after the second dose), with the most common being urticaria/angioedema, pityriasis rosea, herpes zoster, and maculopapular rash. After BioNTech, 39 non‐local cutaneous reactions were observed to have developed (24.8% after the first dose and 5% after the second dose), and the most common were herpes zoster, delayed large local reaction, pityriasis rosea, and urticaria/angioedema in order of frequency. Existing autoimmune diseases were triggered in 2.1% of the patients vaccinated with CoronaVac and 8.2% of those vaccinated with BioNTech.ConclusionsThere are no comprehensive data on cutaneous adverse reactions specific to the CoronaVac vaccine. We determined the frequency of adverse reactions from the dermatologist's point of view after CoronaVac and BioNTech vaccination and identified a wide spectrum of non‐local cutaneous reactions. Our data show that CoronaVac is associated with less harmful reactions while BioNTech may result in more serious reactions, such as herpes zoster, anaphylaxis, and triggering of autoimmunity. However, most of these reactions were self‐limiting or required little therapeutic intervention. |
| Anahtar Kelimeler |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları |